Lou Wangzhouyang, Li Yunsheng
Chun'an County First People's Hospital, Hangzhou, 311700, People's Republic of China.
Heliyon. 2024 Aug 5;10(15):e35686. doi: 10.1016/j.heliyon.2024.e35686. eCollection 2024 Aug 15.
Lung cancer is a highly prevalent cancer on a global scale and its oncogenic process is driven by the accumulation of multiple pathological events. Epigenetics has gained significant recognition in recent years as a crucial contributor to the development of lung cancer. Epigenetics include processes such as DNA methylation, histone modification, chromatin remodeling, and RNA modification. These pathways lead to enduring alterations in genetic phenotypes, which are crucial in the advancement and growth of lung cancer. However, the specific mechanisms and roles of epigenetics in lung cancer still need to be further elucidated.
We obtained publications from the Web of Science databases and applied a rigorous search method to filter them. Ultimately, we gathered high-quality publications that had received the highest 100 number of citations. The data were processed and visualized by various bibliometric tools.
The 100 papers had varying numbers of citations, with the lowest being 491 and the most being 6316. On average, each work received 1119 citations. A total of 1056 co-authors were involved in publishing these papers in 59 journals from 185 institutions in 27 countries. The majority of high-caliber research in the subject of lung cancer epigenetics is conducted in advanced countries, with the United States taking the lead in terms of both the quantity of articles produced and their academic influence. The study of DNA methylation has been a longstanding research priority in the discipline. With the development of next-generation sequencing technology in recent years, research related to non-coding RNA has become a research hotspot. Future research directions may focus more on exploring the mechanisms of action of messenger RNA and circular RNA and developing targeted treatment strategies based on non-coding RNA drugs.
We analyzed 100 top lung cancer and epigenetics documents through various bibliometric analysis tools. This study provides a concise overview of the findings from prior research, anticipates future research directions, and offers potential avenues for additional investigation.
肺癌是全球范围内高度流行的癌症,其致癌过程由多种病理事件的积累驱动。近年来,表观遗传学作为肺癌发生发展的关键因素已得到广泛认可。表观遗传学包括DNA甲基化、组蛋白修饰、染色质重塑和RNA修饰等过程。这些途径导致遗传表型的持久改变,这对肺癌的进展和生长至关重要。然而,表观遗传学在肺癌中的具体机制和作用仍需进一步阐明。
我们从科学网数据库获取出版物,并应用严格的搜索方法进行筛选。最终,我们收集了被引次数最高的100篇高质量出版物。数据通过各种文献计量工具进行处理和可视化。
这100篇论文的被引次数各不相同,最少为491次,最多为6316次。平均每篇论文被引1119次。共有1056位共同作者参与在27个国家185个机构的59种期刊上发表这些论文。肺癌表观遗传学领域的大多数高水平研究在发达国家进行,美国在论文数量及其学术影响力方面均居领先地位。DNA甲基化的研究一直是该学科长期以来的研究重点。近年来,随着下一代测序技术的发展,与非编码RNA相关的研究已成为研究热点。未来的研究方向可能更多地集中在探索信使RNA和环状RNA 的作用机制,以及基于非编码RNA药物开发靶向治疗策略。
我们通过各种文献计量分析工具分析了100篇顶级肺癌与表观遗传学文献。本研究简要概述了先前研究的结果,预测了未来的研究方向,并为进一步研究提供了潜在途径。